Concepedia

Faisal Sohail

FS

Statistics

Publications

6

Citations

986

H-Index

6

Active since

2015

Affiliations

Alexion Pharmaceuticals (United States)(Current)

Fondazione IRCCS Istituto Neurologico Carlo Besta

University of North Carolina at Chapel Hill

National Hospital Organization Hanamaki Hospital

International University of Health and Welfare

Faisal Sohail is an author at Alexion Pharmaceuticals (United States) specializing in myasthenia gravis pharmacotherapy, pharmacology, and anti-acetylcholine receptor antibodies.

ORCID

Publications per year

2015–2022

6

Publications

6

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 800 citations

, , +6

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

Renato Mantegazza, Gil I. Wolfe, Srikanth Muppidi et al. · Neurology · 2020 · 79 citations · Full text

, , +9

Eculizumab improves fatigue in refractory generalized myasthenia gravis

Henning Andersen, Renato Mantegazza, Jing Jing Wang et al. · Quality of Life Research · 2019 · 56 citations · Full text

, , +14

Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study

Hiroyuki Murai, Akiyuki Uzawa, Yasushi Suzuki et al. · Journal of the Neurological Sciences · 2019 · 23 citations · Full text

, , +14

The Composition of Long-term Unemployment Is Changing toward Older Workers

Alexander Monge‐Naranjo, Faisal Sohail · The Regional Economist · 2015 · 14 citations

, , +8

1–5 of 6